ArticleComputational and structural biotechnology journal2020
A mathematical model to predict nanomedicine pharmacokinetics and tumor delivery.
Article in Computational and structural biotechnology journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 101 citations in OpenAlex.
- Preclinical Pharmacokinetic-Pharmacodynamic Modeling of Antibody Nanoconjugates for Breast Cancer Treatment.CPT: pharmacometrics & systems pharmacology · 2026Article
- From bench to bedside: Overcoming translational hurdles in nanoparticle research with pharmacokinetic modeling.Bioengineering & translational medicine · 2026Review
- Myocardial Ischemia-Reperfusion Injury: Molecular Mechanisms and Innovative Therapeutic Strategies.Reviews in cardiovascular medicine · 2026Review
- Nanomedicine Strategies Against Biofilm-Associated Infections: Advances, Challenges, and Translational Barriers.MicrobiologyOpen · 2026Review
- Drug-loaded nanoparticles for cancer therapy: A high-throughput multicellular agent-based modeling study.Journal of theoretical biology · 2026Article
- Informing development of brain cancer therapies within "preclinical trials" using ex vivo patient tumors.Advanced drug delivery reviews · 2026Review
- Prediction of silica nanoparticle biodistribution using a calibrated physiologically based model: Unbound fraction and elimination rate constants for the kidneys and phagocytosis identified as major determinants.International journal of clinical pharmacology and therapeutics · 2025Article
- Rational design of immunogenic nanoparticles as a platform to reduce ovarian tumor burden in mice.International journal of pharmaceutics · 2025Article
- Emerging applications of nanotechnology in the treatment of acute kidney injury.Nanomedicine (London, England) · 2025Review
- Human nerve growth factor delivery to the retina: Quantitative methodology and mathematical modeling in preclinical settings.PNAS nexus · 2025Article
- Rational Design of Safer Inorganic Nanoparticles via Mechanistic Modeling-Informed Machine Learning.ACS nano · 2025Article
- Rational Design of Immunogenic Nanoparticles as a Platform for Enhanced Ovarian Cancer Immunotherapy in Mice.bioRxiv : the preprint server for biology · 2025Article
- Using mathematical modelling and AI to improve delivery and efficacy of therapies in cancer.Nature reviews. Cancer · 2025Review
- PBPK model of pegylated liposomal doxorubicin to simultaneously predict the concentration-time profile of encapsulated and free doxorubicin in tissues.Drug delivery and translational research · 2025Article
- Rational Design of Safer Inorganic Nanoparticles via Mechanistic Modeling-informed Machine Learning.Research square · 2025Article
- Review
- Digital twins in healthcare: a comprehensive review and future directions.Frontiers in digital health · 2025Review
- Smart CAR-T Nanosymbionts: archetypes and proto-models.Frontiers in immunology · 2025Review
- Predicting tissue distribution and tumor delivery of nanoparticles in mice using machine learning models.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling of Nanomaterials.ACS pharmacology & translational science · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Towards clinical translation of cancer nanomedicine, it is important to systematically investigate the various parameters related to nanoparticle (NP) physicochemical properties, tumor characteristics, and inter-individual variability that affect the tumor delivery efficiency of therapeutic nanomaterials. Comprehensive investigation of these parameters using traditional experimental approaches is impractical due to the vast parameter space; mathematical models provide a more tractable approach to navigate through such a multidimensional space. To this end, we have developed a predictive mathematical model of whole-body NP pharmacokinetics and their tumor delivery
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.